Skip to main
ERAS
ERAS logo

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Erasca Inc. is demonstrating strong potential for positive financial performance due to the promising results from its product pipeline, particularly Naporafenib, ERAS-007, and ERAS-601, which target critical nodes of the RAS/MAPK pathway. The company has reported significant efficacy in its combination studies, showing tumor growth inhibition of 77–83% as monotherapy, coupled with increased effectiveness when combined with treatments like cetuximab and anti-PD-1 checkpoint blockade. Additionally, recent presentations at the 2025 AACR Annual Meeting highlighted compelling preclinical data that further reinforce Erasca’s leadership in precision oncology, focusing on innovative therapies for RAS/MAPK pathway-driven cancers.

Bears say

Erasca Inc. faces a challenging financial outlook primarily due to the inherent risks associated with being a clinical-stage company reliant on the successful development and commercialization of its therapies, which are yet to generate revenue. The uncertainty surrounding the clinical trial outcomes for its lead candidates, Naporafenib and ERAS-007, coupled with significant research and development expenditures, places strain on the company's financial stability. Additionally, the competitive landscape within the oncology sector may hinder Erasca's ability to achieve milestones and secure necessary funding for future endeavors, impacting investor confidence and stock performance.

Erasca Inc (ERAS) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 7 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.